Layne Hartnell, PA
Medical · Mount Vernon, OHNPI 1548906209
Payments from drug & device makers
Across 717 payments — averaging $18.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$4K
- Johnson & Johnson$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Alkermes, Inc.$896
- Otsuka America Pharmaceutical, Inc.$748
- Vanda Pharmaceuticals Inc.$733
- plus $4K from 21 others
What the payments were for
- Travel & lodging$1,1699%
- Food & beverage$11,97790%
- Education$1401%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 264 | $4,054 |
| Johnson & Johnson | 34 | $1,795 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 55 | $1,145 |
| Alkermes, Inc. | 53 | $896 |
| Otsuka America Pharmaceutical, Inc. | 41 | $748 |
| Vanda Pharmaceuticals Inc. | 41 | $733 |
| Teva Pharmaceuticals USA, Inc. | 38 | $584 |
| Supernus Pharmaceuticals, Inc. | 54 | $504 |
| Axsome Therapeutics, Inc. | 13 | $455 |
| Neurocrine Biosciences, Inc. | 20 | $320 |
| E.r. Squibb & Sons, L.L.C. | 9 | $315 |
| Lilly USA, LLC | 8 | $256 |
| Collegium Pharmaceutical, Inc. | 21 | $239 |
| Idorsia Pharmaceuticals US Inc | 10 | $235 |
| Lundbeck LLC | 12 | $167 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $164 |
| Noven Therapeutics, LLC | 5 | $102 |
| Livanova USA, Inc. | 4 | $87 |
| Neos Therapeutics, LP | 4 | $84 |
| Tris Pharma Inc | 4 | $76 |
| Corium, LLC | 4 | $73 |
| Almatica Pharma LLC | 4 | $72 |
| USWM, LLC | 2 | $63 |
| Ironshore Pharmaceuticals Inc. | 3 | $46 |
| Avion Pharmaceuticals | 2 | $33 |
| Brainsway USA Inc | 1 | $30 |
| Vertical Pharmaceuticals, LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$13,286 in reported general payments places this provider in the 95th percentile of 547 medical providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CaplytaLumateperone Tosylate | 20 | $44,171 |
| VraylarCariprazine Hcl | 11 | $17,192 |
| LybalviOlanzapine/Samidorphan Malate | 11 | $16,538 |
| VyvanseLisdexamfetamine Dimesylate | 13 | $4,832 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 26 | $2,903 |
| Olanzapine | 15 | $622 |
| Duloxetine Hcl | 19 | $462 |
| Gabapentin | 44 | $380 |
| Lithium Carbonate ErLithium Carbonate | 20 | $351 |
| Quetiapine Fumarate | 31 | $267 |
| Aripiprazole | 13 | $250 |
| Lorazepam | 41 | $184 |
| Lithium Carbonate | 16 | $177 |
| Sertraline Hcl | 35 | $167 |
| Clonazepam | 28 | $167 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $1,145 | $44,17120 claims |
| AbbVieVraylar | $4,054 | $17,19211 claims |
| Alkermes, Inc.Lybalvi | $896 | $16,53811 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $164 | $4,83213 claims |
| Lilly USA, LLCOlanzapine | $256 | $62215 claims |
| Almatica Pharma LLCSertraline Hcl | $72 | $16735 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 547 medical providers in Ohio.
Other medical in Mount Vernon
- Shannon GhizzoniColumbus$116K
- Susan WhittCanal Winchester$74K
- Christopher FrickLima$46K
- Kodi VealeAkron$43K
- Abbey BlairCleveland$24K
- Joana ZulaConcord Twp$23K
- Chelsea AustenColumbus$21K
- Kristen FairchildToledo$19K
- Kaitlin SchuppGahanna$17K
- Melanie HunglerCincinnati$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.